Article

Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies.

Departments of Clinical Pharmacology, Pharmacokinetics, Groton/New London, Connecticut, Sandwich, UK.
Molecular Pharmaceutics (Impact Factor: 4.57). 12/2009; 7(2):398-411.
Source: PubMed

ABSTRACT The objective of this work was to further investigate the reasons for disconcordant clinical digoxin drug interactions (DDIs) particularly for false negative where in vitro data suggests no P-glycoprotein (P-gp) related DDI but a clinically relevant DDI is evident. Applying statistical analyses of binary classification and receiver operating characteristic (ROC), revised cutoff values for ratio of [I]/IC(50) < 0.1 and [I(2)]/IC(50) < 5 were identified to minimize the error rate, a reduction of false negative rate to 9% from 36% (based on individual ratios). The steady state total C(max) at highest dose of the inhibitor is defined as [I] and the ratio of the nominal maximal gastrointestinal concentration determined for highest dose per 250 mL volume defined [I(2)](.) We also investigated the reliability of the clinical data to see if recommendations can be made on values that would allow predictions of 25% change in digoxin exposure. The literature derived clinical digoxin interaction studies were statistically powered to detect relevant changes in exposure associated with digitalis toxicities. Our analysis identified that many co-meds administered with digoxin are cardiovascular (CV) agents. Moreover, our investigations also suggest that the presence of CV agents may alter cardiac output and/or kidney function that may act alone or are additional components to enhance digoxin exposure along with P-gp interaction. While we recommend digoxin as the probe substrate to define P-gp inhibitory potency for clinical assessment, we observed high concordance in P-gp inhibitory potency for calcein AM as a probe substrate.

0 Bookmarks
 · 
77 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The multidrug resistance protein 1 (MDR1) is known to limit drug brain penetration and be a key player in drug-drug interactions (DDI). Theoretical cutoffs from regulatory guidelines are used to extrapolate MDR1 interactions from in vitro to in vivo. However, these cut-offs do not account for inter-laboratory variability. Our aim was to calibrate our experimental system to allow better in vivo predictions. 166 CNS and non-CNS drugs were selected to calibrate the MDR1 transport screening assay using LLC-PK1 cells overexpressing MDR1 (L-MDR1). A threshold efflux ratio (ER) of 2 was established as one parameter to assess brain penetration in lead optimization. The inhibitory potential of 57 molecules was evaluated using IC50 values based on digoxin ER (IC50(ER)) or permeability (IC50(Papp)) in L-MDR1 cells. Published clinical data for 68 DDIs involving digoxin as the victim drug were collected. DDI risk assessments were based on intestinal concentrations ([I2]), as well as, unbound [I1u] and total plasma [I1T] concentrations. A receiver operating characteristic analysis identified an [I2]/IC50(ER) of 6.5 as the best predictor of a potential interaction with digoxin in patients. The model was further evaluated with a test set of 11 digoxin DDIs and 16 non-digoxin DDIs, resulting in only 1 false negative for each test set, no false positive among the digoxin DDIs and 2 among the non-digoxin DDIs. Future refinements might include using cerebrospinal fluid to unbound plasma concentration ratios rather than therapeutic class, better estimation of [I2] or dynamic modeling of MDR1-mediated DDIs.
    Drug metabolism and disposition: the biological fate of chemicals 06/2014; · 3.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A strategy for assessing potential drug-drug interactions (DDIs) based on a simulated intestinal concentration was described. The proposed prediction method was applied to the DDI assessment of luseogliflozin, a novel antidiabetic drug, against miglitol absorbed via the intestinal sodium-glucose cotransporter 1 (SGLT1). The method involves four steps: [step1], collection of physicochemical and pharmacokinetic parameters of luseogliflozin for use in a computer simulation; [step2], evaluation of the validity of these parameters by verifying the goodness-of-fit between simulated and observed plasma profiles; [step3], simulation of the intestinal luseogliflozin concentration-time profile using the ACAT model in GastroPlus(TM) and estimation the time spent above a value 10-fold higher than the IC50 value (TAIC) for SGLT1; and [step4], the evaluation of the DDI potential of luseogliflozin by considering the percentage of TAIC against the miglitol Tmax value (TAIC/Tmax). An initial attempt to prove the validity of this method was performed in rats. The resulting TAIC/Tmax in rats was 32%, suggesting a low DDI potential of luseogliflozin against miglitol absorption. The validity was then confirmed using an in vivo interaction study in rats. In humans, luseogliflozin was expected to have no DDI potential against miglitol absorption, since the TAIC/Tmax in humans was lower than that in rats. This prediction was proven, as expected, in a clinical interaction study. In conclusion, the present strategy based on a simulation of the intestinal concentration-time profile using dynamic modeling would be useful for assessing the clinical DDI potential of a concomitant agent against drugs absorbed via an intestinal transporter.
    Drug metabolism and disposition: the biological fate of chemicals 07/2014; 42(9). · 3.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The "P-glycoprotein" IC50 working group reported an 18- to 796-fold interlaboratory range in digoxin transport IC50 (inhibitor concentration achieving 50% of maximal inhibition), raising concerns about the predictability of clinical transporter-based drug-drug interactions (DDIs) from in vitro data. This Commentary describes complexities of digoxin transport, which involve both uptake and efflux processes. We caution against attributing digoxin transport IC50 specifically to P-glycoprotein (P-gp) or extending this composite uptake/efflux IC50 variability to individual transporters. Clinical digoxin interaction studies should be interpreted as evaluation of digoxin safety, not P-gp DDIs.
    Clinical Pharmacology &#38 Therapeutics 09/2014; 96(3):298-301. · 7.39 Impact Factor